Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%

Vijaya Diagnostic Q4FY26 revenue jumps 27%, EBITDA margin expands to 43.5%

By: IPP Bureau

Last updated : May 08, 2026 12:32 pm



With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion


Vijaya Diagnostic Centre Limited has reported strong financial and operational performance for the quarter and financial year ended March 31, 2026, driven by healthy growth in test volumes, network expansion, and improved operational efficiencies.

The company posted consolidated revenue from operations of Rs 219.4 crore in Q4FY26, registering a 26.6% year-on-year increase compared to Rs 173.2 crore in the corresponding quarter last year.

EBITDA for the quarter rose 38.7% year-on-year to Rs 95.5 crore, while EBITDA margin expanded by 379 basis points to 43.5%. Profit after tax increased 37.5% to Rs 47.9 crore, with PAT margin improving to 21.8%.

For the full financial year FY26, Vijaya Diagnostic reported revenue from operations of Rs 814.2 crore, reflecting a 19.5% year-on-year increase. EBITDA rose 23.3% to Rs 336.9 crore, while EBITDA margin improved to 41.4%.

Annual profit after tax grew 20.3% year-on-year to Rs 173 crore. During FY26, the company conducted 16.92 million tests and recorded 4.68 million footfalls across its network.

Commenting on the performance, Suprita Reddy, MD & CEO, Vijaya Diagnostic Centre, said, “FY26 was a landmark year for the company as revenue crossed Rs 800 crore, supported by sustained growth momentum and disciplined execution. The company achieved a five-year CAGR of 16.5% since listing, surpassing its long-term guidance.”

Looking ahead to FY27, Vijaya Diagnostic plans to expand its network by adding 4–5 hubs and 10–12 spokes. The company is also establishing a fully automated laboratory with track infrastructure at Panjagutta in Hyderabad and plans to introduce advanced genomic testing capabilities.

 

 

Vijaya Diagnostic Centre Limited Vijaya Diagnostic Q4FY26 results Vijaya Diagnostic FY26 earnings diagnostic chain pathology business radiology diagnostics healthcare diagnostics EBITDA margin expansion PAT growth revenue growth diagnostic testing healthcare sector AI diagnostics genomic testing Hyderabad diagnostics market Suprita Reddy medical diagnostics company NSE VIJAYA BSE 543350 healthcare stocks India diagnostics industry automated laboratory network expansion

First Published : May 08, 2026 12:00 am